INVESTIGATORS from all over the world are keen to recruit into the ONTARGET / TRANSCEND trials as study results which are expected to be available by 2007 will provide reliable answers to important clinical questions and contribute to evidence-based medicine on cardiovascular (heart) protection.
ONTARGET/TRANSCEND is one of the largest, most ambitious clinical study programmes to investigate the role of the angiotensin II receptor blocker (ARB) telmisartan and an ACE inhibitor (ACEI) alone or in combination in the prevention of stroke, myocardial infarction, and cardiovascular death.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
